Abstract: The present invention relates to a pharmaceutical vaccine composition comprising: (a) a pathogen-derived antigen selected from the group consisting of Mycobacterium tuberculosis antigen, Bacillus anthracis antigen, HAV (hepatitis A virus) antigen, HBV (hepatitis B virus) antigen, HCV (hepatitis C virus) antigen, HIV (human immunodeficiency virus) antigen, influenza virus antigen, HSV (herpes simplex virus) antigen, Hib (Haemophilus influenzae type b) antigen, Neisseria meningitidis antigen, Corynebacterium diphtheriae antigen, Bordetella pertussis antigen, Clostridium tetani antigen and Varicella virus antigen; (b) a deacylated non-toxic LOS (lipooligosaccharide); and (c) a pharmaceutically acceptable carrier.

Abstract: The present invention relates to a dual centrifugal chiller, and it is an object of the present invention to provide a dual centrifugal chiller which is configured so that a turbo chiller having two compressors, two evaporators and two condensers lowers the head of the compressors, and that the compressors are operated with the same heads. The above object can be accomplished by the provision of a dual centrifugal chiller in which chilled water passes through a first evaporator and then through a second evaporator, cooling water passes through a first condenser and then through a second condenser, a first compressor accommodating a refrigerant connects said first evaporator and said second condenser, and a second compressor accommodating a refrigerant connects said second evaporator and said first condenser.

Abstract: Disclosed is an adjuvant composition of the present invention including the oligodeoxynucleotides and the LPS-derived non-toxic polysaccharides as the major components.